Image

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Trial of HQP1351 for resistant CML and Ph+ ALL patients.

Recruiting
18 years and older
All
Phase 1

Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) are types of blood cancer. This study tests a drug called HQP1351 on patients who have these cancers and have not responded well to other medicines called Tyrosine Kinase Inhibitors (TKIs). TKIs are drugs that block cancer cell growth.

In the study, patients will be divided into groups to receive different doses of HQP1351. Some patients might also receive another drug called Blinatumomab, which helps the immune system fight cancer. The study will check the medicine's safety and how it moves through the body.

  • Study Duration: Patients will take HQP1351 every two days for 28 days (1 cycle), with some receiving additional cycles.
  • Eligibility: Patients must have tried at least two other TKIs and not responded.
  • Risks: Close monitoring for side effects, especially in high-dose groups.

Participation involves several visits for tests and monitoring. It's important to discuss with a doctor to understand the potential benefits and risks.

Study details
    Leukemia
    Myeloid
    Chronic
    Myeloid Leukemia
    Chronic Myeloid Leukemia
    Philadelphia Positive Acute Lymphoblastic Leukemia
    B Cell Precursor Type Acute Leukemia

NCT04260022

Ascentage Pharma Group Inc.

13 December 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

  Other languages supported:

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.